CRISPR THERAPEUTICS AG (CRSP) Return on equity 2016–2025
CRISPR THERAPEUTICS AG (CRSP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-30.3%FY2025 · since FY2016: -10.0% → -30.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -30.3% | -11.3 pp |
| FY2024 | -19.0% | -10.8 pp |
| FY2023 | -8.2% | +26.5 pp |
| FY2022 | -34.7% | -50.4 pp |
| FY2021 | 15.7% | +36.7 pp |
| FY2020 | -21.0% | -28.1 pp |
| FY2019 | 7.1% | +49.2 pp |
| FY2018 | -42.1% | -5.7 pp |
| FY2017 | -36.4% | -26.4 pp |
| FY2016 | -10.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net incomeCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating incomeCRSP Operating marginCRSP Operating cash flowCRSP Free cash flowCRSP Capital expendituresCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Total liabilitiesCRSP Shareholders’ equityCRSP overview →